| Overall | Ability to access to NSP syringes‡ | χ2-test | Venue stratification | χ2-test | ||||
---|---|---|---|---|---|---|---|---|---|
 |  | <40% | 40-70% | >70% | (χ2, p-value) | MDC | Community | NSP | (χ2, p value) |
 | N (%) | N (%) | N (%) | N (%) |  | N (%) | N (%) | N (%) |  |
Used drugs in the last 30 days (n = 402)* | |||||||||
Yes | 398 (99.0) | 139 (97.9) | 55 (100) | 204 (99.5) | Â | 74 (94.9) | 171 (100) | 153 (100) | Â |
No | 4 (1.0) | 3 (2.1) | 0 (0) | 1 (0.5) | 2.89, p = 0.236 | 4 (5.1) | 0 (0) | 0 (0) | 16.782, p < 0.001†|
Frequency of injecting drugs in the last 30 days (n = 392) | |||||||||
<1 times / day | 41 (10.5) | 12 (8.8) | 4 (7.4) | 25 (12.4) | Â | 7 (9.6) | 19 (11.1) | 15 (10.1) | Â |
1-2 times / day | 220 (56.1) | 68 (50.0) | 21 (38.9) | 131 (64.9) | Â | 37 (50.7) | 109 (63.7) | 74 (50.0) | Â |
3-5 times / day | 115 (29.3) | 46 (33.8) | 28 (51.9) | 41 (20.3) | Â | 22 (30.1) | 39 (22.8) | 54 (36.5) | Â |
>6 times / day | 16 (4.1) | 10 (7.4) | 1 (1.9) | 5 (2.5) | 29.439, p < 0.001†| 7 (9.6) | 4 (2.3) | 5 (3.4) | 15.236, p = 0.019†|
Times of repeated use per needle/syringe before disposal in the last 30 days (n = 389) | |||||||||
0 | 4 (1.0) | 0 (0) | 3 (5.9) | 1 (0.5) | Â | 0 (0) | 0 (0) | 4 (2.7) | Â |
1 | 248 (63.8) | 81 (58.7) | 26 (51.0) | 141 (70.5) | Â | 49 (66.2) | 111 (65.7) | 88 (60.3) | Â |
2-5 | 131 (33.7) | 54 (39.1) | 22 (43.1) | 55 (27.5) | Â | 21 (28.4) | 57 (33.7) | 53 (36.3) | Â |
6-9 | 1 (0.3) | 1 (0.7) | 0 (0) | 0 (0) | Â | 1 (1.4) | 0 (0) | 0 (0) | Â |
≥10 | 5 (1.3) | 2 (1.4) | 0 (0) | 3 (1.5) | 6.84, p = 0.033†| 3 (4.1) | 1 (0.6) | 1 (0.7) | 0.151, p = 0.927 |
Average ± SD | 1.62 ± 1.32 | 1.80 ± 1.45 | 1.55 ± 0.86 | 1.52 ± 1.31 |  | 1.93 ± 2.00 | 1.54 ± 1.05 | 1.56 ± 1.13 |  |
Shared syringes in the last 30 days (n = 400) | |||||||||
Yes | 35 (8.8) | 23 (16.3) | 7 (12.7) | 5 (2.5) | Â | 15 (19.5) | 4 (2.3) | 16 (10.5) | Â |
No | 365 (91.2) | 118 (83.7) | 48 (87.3) | 199 (97.5) | 21.326, p < 0.001†| 62 (80.5) | 167 (97.7) | 136 (89.5) | 20.507, p < 0.001†|
Number of times shared syringes in the last 30 days (n = 29) | |||||||||
1 | 10 (34.5) | 9 (45.0) | 1 (16.7) | 0 (0) | Â | 8 (66.7) | 0 (0) | 2 (15.4) | Â |
2-5 | 16 (55.2) | 9 (45.0) | 5 (83.3) | 2 (66.7) | Â | 4 (33.3) | 3 (75.0) | 9 (69.2) | Â |
≥6 | 3 (10.3) | 2 (10.0) | 0 (0) | 1 (33.3) | 4.83, p = 0.090 | 0 (0) | 1 (25.0) | 2 (15.4) | 5.780, p = 0.056 |
Average ± SD | 4.28 ± 6.85 | 4.15 ± 7.37 | 2.17 ± 0.98 | 9.33 ± 9.29 |  | 1.55 ± 0.93 | 6.75 ± 8.85 | 5.92 ± 8.78 |  |
Number of sharing partners in the last 30 days (n = 31) | |||||||||
1 | 10 (31.3) | 5 (22.7) | 5 (71.4) | 0 (0) | Â | 4 (28.6) | 1 (25.0) | 5 (35.7) | Â |
2-5 | 20 (62.5) | 15 (68.3) | 2 (28.6) | 3 (100) | Â | 9 (64.3) | 3 (75.0) | 8 (57.1) | Â |
6-9 | 1 (3.1) | 1 (4.5) | 0 (0) | 0 (0) | Â | 0 (0) | 0 (0) | 1 (7.1) | Â |
≥10 | 1 (3.1) | 1 (4.5) | 0 (0) | 0 (0) | 6.73, p = 0.035†| 1 (7.1%) | 0 (0) | 0 (0) | 0.594, p = 0.743 |
Average ± SD | 2.53 ± 1.98 | 2.82 ± 2.26 | 1.43 ± 0.79 | 3.00 ± 0.0 |  | 2.64 ± 2.50 | 2.25 ± 0.96 | 2.85 ± 1.99 |  |
Maximum number of group sharing partners in the last 30 days (n = 32) | |||||||||
1 | 2 (6.3) | 1 (4.5) | 1 (14.3) | 0 (0) | Â | 1 (7.1) | 0 (0) | 1 (7.1) | Â |
2-5 | 28 (87.5) | 20 (90.9) | 5 (71.4) | 3 (100) | Â | 13 (92.9) | 4 (100) | 11 (78.6) | Â |
6-9 | 2 (6.3) | 1 (4.5) | 1 (14.3) | 0 (0) | 3.19, p = 0.203 | 0 (0) | 0 (0) | 2 (14.3) | 0.867, p = 0.648 |
Average ± SD | 2.94 ± 1.68 | 2.86 ± 1.42 | 3.00 ± 2.71 | 3.33 ± 0.58 |  | 2.50 ± 0.76 | 2.50 ± 0.58 | 3.50 ± 2.35 |  |